Gut Microbes: Regulating uric acid
Certain strains of a bacterium found in the gut of some animals, Lactobacillus plantarum, are able to counter hyperuricemia, a condition caused by high levels of uric acid in the blood.
- College of Animal Sciences, Zhejiang University, China
Improvements in the quality of life have led to an increase in the incidence of hyperuricemia, a medical condition that can lead to kidney stones and gout, with cases increasingly affecting younger individuals (Johnson et al., 2018; Zhang et al., 2019). Hyperuricemia – the presence of abnormally high levels of uric acid in the blood – arises from interactions between the liver, the kidneys and the gut, which has a role in removing uric acid from the body (Dalbeth et al., 2021; Niu et al., 2018; Yun et al., 2017). Studies indicate that gut microbes are crucial to uric acid metabolism, and interventions such as probiotics, prebiotics and fecal microbiota transplants can help reduce hyperuricemia by altering the gut microbiota (Cao et al., 2022a; Wang et al., 2022; Zhao et al., 2022).
It has been shown that various strains of bacteria can alleviate hyperuricemia through two mechanisms: the direct hydrolysis of uric acid, and the hydrolase-mediated degradation of nucleosides that are the precursors of uric acid in the intestine. Limosilactobacillus fermentum JL-3 – a strain isolated from Chinese mud water – is capable of the hydrolysis of uric acid (Wu et al., 2021), whereas various strains of Lactobacillus, a well-known genus of bacteria, reduce uric acid levels through the hydrolysis of nucleosides in the intestine: these strains include L. paracasei (X11; Cao et al., 2022b) and strains of L. plantarum derived from Chinese sauerkraut (DM9218-A; Li et al., 2014) and Chinese mustard (GKM3; Hsu et al., 2019).
Recent studies have revealed that gene cloning can be used to identify specific hydrolases involved in the degradation of nucleosides for L. plantarum and L. aviarius (Li et al., 2023b; Li et al., 2023a). However, the precise mechanisms underlying the hydrolysis of the nucleoside precursors of uric acid have remained unclear. Now, in eLife, Wence Wang (South China Agricultural University), Qiang Tu (Shandong University) and colleagues – including Yang Fu as first author – report the results of in vitro studies and experiments on geese and mice that shed new light on the hydrolysis of these precursors (Fu et al., 2024).
The team isolated a strain called L. plantarum SQ001 from geese with hyperuricemia, and a genome-wide analysis revealed the presence of four genes that code for nucleoside hydrolysis-related enzymes (iunH, yxjA, rihA, rihC). In vitro experiments revealed that one of these enzymes, iunH, effectively catalyzes the hydrolysis of nucleosides, such as inosine and guanosine, converting them to nucleobases, as evidenced by metabolomics analysis. The hydrolysis mechanism was further validated through experiments that involved knocking out the gene for iunH in L. plantarum SQ001, and expressing it in E. coli. Although nucleosides are hydrolyzed to produce nucleobases, the direct link between this process and the reduction of uric acid remains unclear, possibly due to the transport of nucleosides and nucleobases in the gut. It may be that the lower uptake of these substances reduces the synthesis and accumulation of uric acid.
The team validated the functionality of L. plantarum SQ001 by establishing models of hyperuricemia in both geese and mice (Figure 1), and showed that this particular strain significantly enhanced the abundance of Lactobacillus in the gut of the host, which alleviated the symptoms of hyperuricemia by reducing the synthesis of uric acid and increasing its excretion. The fact that hyperuricemia was alleviated in mice may help with efforts to develop new ways to treat hyperuricemia and gout in humans.
Figure 1
Lactobacillus plantarum reduces uric acid synthesis through the hydrolysis of nucleosides.
A strain of the bacterium L. plantarum was isolated from the large intestine of geese with hyperuricemia, a condition caused by the presence of abnormally high levels of uric acid in the blood (top left). In vitro experiments showed that the presence of the bacteria led to an increase in the degradation of nucleosides that are precursors of uric acid. Administering the bacteria to healthy geese and mice (top right) also led to a reduction in the levels of uric acid in the blood. Other experiments showed that L. plantarum absorbed the nucleosides, and that an enzyme called iunH broke down the nucleosides to produce nucleobases (bottom).
Figure created with figdraw.com.
References
-
Lactobacillus paracasei X11 ameliorates hyperuricemia and modulates gut microbiota in miceFrontiers in Immunology 13:940228.https://doi.org/10.3389/fimmu.2022.940228
-
Antiobesity and uric acid-lowering effect of Lactobacillus plantarum GKM3 in high-fat-diet-induced obese ratsJournal of the American College of Nutrition 38:623–632.https://doi.org/10.1080/07315724.2019.1571454
-
Inhibition of 3,5,2’,4’-tetrahydroxychalcone on production of uric acid in hypoxanthine-induced hyperuricemic miceBiological & Pharmaceutical Bulletin 41:99–105.https://doi.org/10.1248/bpb.b17-00655
-
The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategiesCritical Reviews in Food Science and Nutrition 62:3979–3989.https://doi.org/10.1080/10408398.2021.1874287
-
Hyperuricemia and cardiovascular diseaseCurrent Pharmaceutical Design 25:700–709.https://doi.org/10.2174/1381612825666190408122557
-
The potential of probiotics in the amelioration of hyperuricemiaFood & Function 13:2394–2414.https://doi.org/10.1039/D1FO03206B
Article and author information
Author details
Publication history
Copyright
© 2024, Hu
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 481
- views
-
- 46
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Gut Microbes: Regulating uric acid
eLife 13:e104493.
https://doi.org/10.7554/eLife.104493
Further reading
-
- Epidemiology and Global Health
- Microbiology and Infectious Disease
Several areas of the world suffer a notably high incidence of Shiga toxin-producing Escherichia coli. To assess the impact of persistent cross-species transmission systems on the epidemiology of E. coli O157:H7 in Alberta, Canada, we sequenced and assembled E. coli O157:H7 isolates originating from collocated cattle and human populations, 2007–2015. We constructed a timed phylogeny using BEAST2 using a structured coalescent model. We then extended the tree with human isolates through 2019 to assess the long-term disease impact of locally persistent lineages. During 2007–2015, we estimated that 88.5% of human lineages arose from cattle lineages. We identified 11 persistent lineages local to Alberta, which were associated with 38.0% (95% CI 29.3%, 47.3%) of human isolates. During the later period, six locally persistent lineages continued to be associated with human illness, including 74.7% (95% CI 68.3%, 80.3%) of reported cases in 2018 and 2019. Our study identified multiple locally evolving lineages transmitted between cattle and humans persistently associated with E. coli O157:H7 illnesses for up to 13 y. Locally persistent lineages may be a principal cause of the high incidence of E. coli O157:H7 in locations such as Alberta and provide opportunities for focused control efforts.
-
- Biochemistry and Chemical Biology
- Microbiology and Infectious Disease
Mycofactocin is a redox cofactor essential for the alcohol metabolism of mycobacteria. While the biosynthesis of mycofactocin is well established, the gene mftG, which encodes an oxidoreductase of the glucose-methanol-choline superfamily, remained functionally uncharacterized. Here, we show that MftG enzymes are almost exclusively found in genomes containing mycofactocin biosynthetic genes and are present in 75% of organisms harboring these genes. Gene deletion experiments in Mycolicibacterium smegmatis demonstrated a growth defect of the ∆mftG mutant on ethanol as a carbon source, accompanied by an arrest of cell division reminiscent of mild starvation. Investigation of carbon and cofactor metabolism implied a defect in mycofactocin reoxidation. Cell-free enzyme assays and respirometry using isolated cell membranes indicated that MftG acts as a mycofactocin dehydrogenase shuttling electrons toward the respiratory chain. Transcriptomics studies also indicated remodeling of redox metabolism to compensate for a shortage of redox equivalents. In conclusion, this work closes an important knowledge gap concerning the mycofactocin system and adds a new pathway to the intricate web of redox reactions governing the metabolism of mycobacteria.
